JPMorgan analyst Jessica Fye reinstates coverage on BeOne Medicines (NASDAQ: ONC) with a Overweight rating and a price target of $415.00.

For an analyst ratings summary and ratings history on BeOne Medicines click here. For more ratings news on BeOne Medicines click here.

Shares of BeOne Medicines closed at $297.01 yesterday.